Phase 2 Study of Neoadjuvant Treatment with Cellular Redox Modulator NOV-002 in Combination with Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) in Patients with Stage II-III HER-2 (-) Breast Cancer

被引：0
|
作者：
Montero, A. J.
Diaz, C. M.
Slingerland, J.
Pegram, M.
Hurley, J.
Welsh, C. F.
Avisar, E.
Seo, P.
Vogel, C. L.
Garrett-Mayer, E.
Hermann, V.
Baker, M. K.
Silva, O.
Koniaris, L.
Rodgers, S.
Schuhwerk, K.
Pazoles, C. J.
Moffat, F.
Cole, D. J.
Gluck, S.
机构：
[1] Univ Miami, Sylvester Comprehens Canc Ctr, Coral Gables, FL 33124 USA
[2] Med Univ S Carolina, Charleston, SC USA
[3] Novelos Therapeut, Newton, MA USA
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-P1-11-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-11-05
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II–IIIc breast cancer
    A. J. Montero
    C. M. Diaz-Montero
    Y. E. Deutsch
    J. Hurley
    L. G. Koniaris
    T. Rumboldt
    S. Yasir
    M. Jorda
    E. Garret-Mayer
    E. Avisar
    J. Slingerland
    O. Silva
    C. Welsh
    K. Schuhwerk
    P. Seo
    M. D. Pegram
    S. Glück
    Breast Cancer Research and Treatment, 2012, 132 : 215 - 223
  • [2] Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer
    Montero, A. J.
    Diaz-Montero, C. M.
    Deutsch, Y. E.
    Hurley, J.
    Koniaris, L. G.
    Rumboldt, T.
    Yasir, S.
    Jorda, M.
    Garret-Mayer, E.
    Avisar, E.
    Slingerland, J.
    Silva, O.
    Welsh, C.
    Schuhwerk, K.
    Seo, P.
    Pegram, M. D.
    Glueck, S.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 132 (01) : 215 - 223
  • [3] Phase II study of neoadjuvant docetaxel/vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer
    Limentani, Steven A.
    Brufsky, Adam M.
    Erban, John K.
    Jahanzeb, Mohammed
    Lewis, Deborah
    CLINICAL BREAST CANCER, 2006, 6 (06) : 511 - 517
  • [4] Biweekly nonpegylated liposomal doxorubicin (M) and docetaxel (T) as neoadjuvant treatment in patients with stage II-III breast cancer
    Alvarez, I.
    Modolell, A.
    Mayordomo, J. I.
    Janariz, J.
    Centelles, M.
    Garcia, J. M.
    Puerto, P.
    Diego, C.
    Madronal, C.
    Burillo-R Andres, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] Multicenter study of nonpegylated liposomal doxorubicin and docetaxel as neoadjuvant treatment in patients with stage II-III breast
    Modolell, A
    Mayordomo, J
    Garcia, JM
    Machengs, I
    Alvarez, I
    Palombo, H
    Yubero, A
    Murillo, L
    Belon, J
    Andres, R
    Burillo, M
    Lambea, J
    Centelles, M
    Tres, A
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S226 - S226
  • [6] Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC®T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC®TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients:: BCIRG 006 study
    Slamon, D
    Eiermann, W
    Robert, N
    Pienkowski, T
    Martin, M
    Pawlicki, M
    Chan, A
    Smylie, M
    Liu, M
    Falkson, C
    Pinter, T
    Fornander, T
    Shiftan, T
    Valero, V
    Von Minckwitz, G
    Mackey, J
    Tabah-Fisch, J
    Buyse, M
    Lindsay, MA
    Riva, A
    Bee, V
    Pegram, M
    Press, M
    Crown, J
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S5 - S5
  • [7] Phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC®T) in Her-2/neu negative early breast cancer patients with positive axillary lymph nodes:: Interim analysis of the BCIRG 005 study
    Eiermann, W
    Pienkowski, T
    Crown, J
    Chap, L
    Pawlicki, M
    Martin, M
    Chan, A
    Saleh, M
    Sehdev, S
    Provencher, L
    Von Minckwitz, G
    Semiglazov, V
    Slamon, D
    Tabah-Fisch, I
    Buyse, M
    Riva, A
    Taupin, H
    Sauter, G
    Mackey, J
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S62 - S63
  • [8] Doxorubicin/pemetrexed followed by docetaxel versus doxorubicin/cyclophosphamide followed by docetaxel as neoadjuvant treatment for early-stage breast cancer:: A randomized phase II trial
    Schneeweiss, Andreas
    Lauschner, Ilka
    Ruiz, Amparo
    Guerrero, Angel
    Sanchez-Rovira, Pedro
    Segui, Miguel Angel
    Goerke, Kay
    Wolf, Michael
    Manikhas, Alexey G.
    Wacker, Juergen
    Marme, Frederik
    Lichter, Peter
    Sinn, Hans-Peter
    Sohn, Christof
    Mansouri, Kambiz
    Bauknecht, Thomas
    Hahn, Meinhard
    CLINICAL BREAST CANCER, 2007, 7 (07) : 555 - 558
  • [9] Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients:: results of a phase II study
    Estevez, L. G.
    Sanchez-Rovira, P.
    Domine, M.
    Leon, A.
    Calvo, I.
    Jaen, A.
    Casado, V.
    Rubio, G.
    Diaz, M.
    Miro, C.
    Lobo, F.
    Carrasco, E.
    Casillas, M.
    Antonio, B. San
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2007, 9 (05): : 317 - 322
  • [10] Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients: results of a phase II study
    L. G. Estévez
    P. Sánchez-Rovira
    M. Dómine
    A. León
    I. Calvo
    A. Jaén
    V. Casado
    G. Rubio
    M. Díaz
    C. Miró
    F. Lobo
    E. Carrasco
    M. Casillas
    B. San Antonio
    Clinical and Translational Oncology, 2007, 9 : 317 - 322
12345